EUTOS Score for Chronic Myelogenous Leukemia (CML)
Predicts outcomes after CML treatments, specifically adjusted for tyrosine kinase treatments.
Use in newly-diagnosed patients before starting therapy.
Management
Though there is no broad consensus on management, a conservative strategy is to treat low-risk patients with imatinib and reserve newer-generation TKIs for high risk patients.
Critical Actions
Can only be applied to a newly-diagnosed patient before starting therapy.